PL2394996T3 - Związki fenyloimidazolowe - Google Patents

Związki fenyloimidazolowe

Info

Publication number
PL2394996T3
PL2394996T3 PL10738531.2T PL10738531T PL2394996T3 PL 2394996 T3 PL2394996 T3 PL 2394996T3 PL 10738531 T PL10738531 T PL 10738531T PL 2394996 T3 PL2394996 T3 PL 2394996T3
Authority
PL
Poland
Prior art keywords
phenylimidazole compounds
phenylimidazole
compounds
Prior art date
Application number
PL10738531.2T
Other languages
English (en)
Inventor
Tadao Shibutani
Koushi Iwata
Satoshi Kido
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2394996T3 publication Critical patent/PL2394996T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL10738531.2T 2009-02-04 2010-02-03 Związki fenyloimidazolowe PL2394996T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009023793 2009-02-04
JP2009255980 2009-11-09

Publications (1)

Publication Number Publication Date
PL2394996T3 true PL2394996T3 (pl) 2016-12-30

Family

ID=42542093

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10738531.2T PL2394996T3 (pl) 2009-02-04 2010-02-03 Związki fenyloimidazolowe

Country Status (21)

Country Link
US (1) US8329739B2 (pl)
EP (1) EP2394996B8 (pl)
JP (1) JP5540227B2 (pl)
KR (1) KR101676889B1 (pl)
CN (1) CN102307861B (pl)
AR (1) AR075245A1 (pl)
AU (1) AU2010211753B2 (pl)
BR (1) BRPI1007902B1 (pl)
CA (1) CA2750704C (pl)
DK (1) DK2394996T3 (pl)
ES (1) ES2587942T3 (pl)
HU (1) HUE028840T2 (pl)
MX (1) MX2011008197A (pl)
MY (1) MY156539A (pl)
PL (1) PL2394996T3 (pl)
PT (1) PT2394996T (pl)
RU (1) RU2497811C2 (pl)
SG (1) SG172895A1 (pl)
TW (1) TWI435871B (pl)
WO (1) WO2010090200A1 (pl)
ZA (1) ZA201104932B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065728A1 (en) 2008-05-14 2011-03-17 Otsuka Pharmaceutical Factory, Inc. Lipoprotein lipase-activating compositions comprising benzene derivatives
EP2550266B1 (en) 2010-03-24 2018-05-09 Amitech Therapeutics Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
US10647688B2 (en) * 2014-12-19 2020-05-12 Galderma Research & Development Compounds, synthesis method thereof and use of same in medicine and in cosmetics
EP4023640A1 (en) * 2015-12-25 2022-07-06 Otsuka Pharmaceutical Factory, Inc. Phenylimidazole compound
CN106946862B (zh) * 2017-03-31 2019-09-03 枣庄学院 1-烷烃-6-甲基-5-硝基-1h-苯并[d]咪唑类化合物及其制备方法
CA3190455A1 (en) * 2020-07-30 2022-02-03 Otsuka Pharmaceutical Factory, Inc. Cold medicine and antiviral medicine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI57407C (fi) * 1971-05-11 1980-08-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av nya farmakologiskt verksamma i 2-staellningen substituerade 4(5)-pyridyl-5(4)-fenyl-imidazoler
DE3411997A1 (de) 1984-03-31 1985-10-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue redox-indikatoren
JP2001226358A (ja) * 1999-10-12 2001-08-21 Japan Tobacco Inc Lpl活性増強剤
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US20110065728A1 (en) 2008-05-14 2011-03-17 Otsuka Pharmaceutical Factory, Inc. Lipoprotein lipase-activating compositions comprising benzene derivatives

Also Published As

Publication number Publication date
TW201033179A (en) 2010-09-16
HUE028840T2 (en) 2017-01-30
RU2011136719A (ru) 2013-03-10
CA2750704A1 (en) 2010-08-12
AU2010211753A1 (en) 2011-07-28
PT2394996T (pt) 2016-08-31
KR101676889B1 (ko) 2016-11-16
CN102307861A (zh) 2012-01-04
MX2011008197A (es) 2011-08-17
MY156539A (en) 2016-02-26
DK2394996T3 (en) 2016-08-01
BRPI1007902A2 (pt) 2020-08-18
EP2394996B1 (en) 2016-06-22
EP2394996A1 (en) 2011-12-14
JPWO2010090200A1 (ja) 2012-08-09
WO2010090200A1 (ja) 2010-08-12
SG172895A1 (en) 2011-08-29
US8329739B2 (en) 2012-12-11
AU2010211753B2 (en) 2015-11-05
HK1160123A1 (en) 2012-08-10
RU2497811C2 (ru) 2013-11-10
CN102307861B (zh) 2014-10-29
TWI435871B (zh) 2014-05-01
AR075245A1 (es) 2011-03-16
KR20110111300A (ko) 2011-10-10
EP2394996A4 (en) 2012-09-12
EP2394996B8 (en) 2016-10-19
US20110275823A1 (en) 2011-11-10
CA2750704C (en) 2016-11-22
ZA201104932B (en) 2012-09-26
BRPI1007902B1 (pt) 2022-01-04
JP5540227B2 (ja) 2014-07-02
ES2587942T3 (es) 2016-10-27

Similar Documents

Publication Publication Date Title
GB0907425D0 (en) Compounds
EP2393493A4 (en) LINKS
GB0918249D0 (en) Compounds
GB0907515D0 (en) Compounds
GB0914856D0 (en) Compounds
GB0915892D0 (en) Compounds
GB0905641D0 (en) Compounds
GB0909671D0 (en) Compounds
ZA201104932B (en) Phenylimidazole compounds
GB0915519D0 (en) Ntithrombotic compounds
GB0909672D0 (en) Compounds
AP2909A (en) Pyrazinoisoquinoline Compounds
GB0911000D0 (en) Compounds
EP2443115A4 (en) COMPOUNDS
GB0910675D0 (en) Compounds
GB0906853D0 (en) Compounds
GB0905060D0 (en) Compounds
GB0908942D0 (en) Compounds
GB0915685D0 (en) Compounds
GB0909912D0 (en) Compounds
GB0908941D0 (en) Compounds
GB0910123D0 (en) Compounds
GB0915686D0 (en) Compounds
GB0912238D0 (en) Compounds
GB0905062D0 (en) Compounds